Insomnia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Global Insomnia Treatment Market Size is Segmented by Treatment Type (Drugs and Devices), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Home right-chevron-icon Market Analysis right-chevron-icon Healthcare Research right-chevron-icon Pharmaceuticals Research right-chevron-icon Disease Specific Drugs Research right-chevron-icon Behavioural Disorder Drugs Research right-chevron-icon Sleep Wake Disorders Research right-chevron-icon Insomnia Treatment Market

Insomnia Treatment Market Size

Insomnia Treatment Market Summary
share button
Study Period 2018 - 2028
Market Size (2023) USD 3.40 Billion
Market Size (2028) USD 4.37 Billion
CAGR (2023 - 2028) 5.16 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Insomnia Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Insomnia Treatment Market Analysis

The Insomnia Treatment Market size is expected to grow from USD 3.40 billion in 2023 to USD 4.37 billion by 2028, at a CAGR of 5.16% during the forecast period (2023-2028).

  • The COVID-19 pandemic brought about unprecedented changes in people's lives. For many, it has caused significant stress, anxiety, and concerns over health, social isolation, employment, finances, and balancing work and family obligations. Such an important life event will likely disrupt sleep and impact market growth. The COVID-19 pandemic impacted sleep.
  • According to the American Academy of Sleep Medicine's (AASM) Sleep Prioritization Survey 2020, about a third of adults (33%) noticed a change in their sleep quality, 30% noticed a change in their ability to fall asleep, and 29% noticed a difference in their nightly amount of sleep. Furthermore, females were more likely than males to report that the COVID-19 pandemic impacted their bedtimes (31% vs. 25%). Such an impact on people's sleep led to the rising demand for insomnia treatment during the pandemic. However, the need for insomnia treatment, even after the pandemic, is expected to remain the same, contributing to the market's growth over the coming five years.
  • Also, the increasing prevalence of insomnia, rising stress levels, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. For instance, an article published in Springer in July 2021 mentioned that the overall prevalence of insomnia was 12.13%, and mild insomnia was 31.97%. The same source noted that most insomnia increased in females compared to males. Such a prevalence of insomnia is expected to drive the market's growth.
  • The rising stress levels among the global population are another primary driver for the market's growth. According to the Health and Safety Executive report published in December 2021, over 822,000 workers suffered from work-related stress, depression, or anxiety in 2020-2021. Such high-stress levels among the population are also expected to drive the market's growth. Insomnia rarely occurs on its own and is frequently associated with other illnesses.
  • Furthermore, innovative product developments for the treatment of insomnia are also expected to contribute to the market's growth. For instance, in June 2022, Pear Therapeutics reported interim follow-up real-world data from a decentralized trail that showed treatment with Somryst, one of the FDA-authorised digital therapeutics for treating chronic insomnia. This device significantly reduced symptoms of insomnia, anxiety, and depression severity.
  • Thus, the factors such as the prevalence of insomnia, rising awareness for treatment, and increasing product launches are expected to contribute to the market's growth over the forecast period. However, misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment are some factors that may limit market growth during the forecast period.

Insomnia Treatment Industry Segmentation

As per the scope of the report, insomnia is a sleep disorder with one or more symptoms that could include fatigue, inability to focus or concentrate, poor memory, mood disturbance, daytime sleepiness, and low motivation or energy. 

The insomnia treatment market is segmented by treatment type (drugs (benzodiazepines, nonbenzodiazepines, orexin antagonists, and other drugs) and devices), distribution channel (hospital pharmacies, retail pharmacies, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type
By Drug
Benzodiazepines
Nonbenzodiazepines
Orexin Antagonist
Other Drugs
Devices
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Insomnia Treatment Market Trends

This section covers the major market trends shaping the Insomnia Treatment Market according to our research experts:

Orexin Antagonist Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period

  • The Orexin antagonist segment is expected to dominate the growth of the studied segment during the forecast period due to the reduced efficacy and harmful side effects that constrain the use of many treatment options for several patients. Some of the orexin receptor antagonists include suvorexant, Lemborexant, and Daridorexant. These drugs are potent dual orexin receptor antagonist that blocks both receptors, i.e., OX1R and OX2R. It stimulates sleep by inhibiting orexin-A and B, neuropeptides that promote wakefulness.
  • Suvorexant (MK-4305, Merck) is one of the first of a new class of drugs for treating insomnia known as ORAs (orexin receptor antagonists). The tablets support the natural transition from sleeplessness to sleep by inhibiting the arousal system's wakefulness-promoting orexin neurons. Suvorexant advances sleep onset, as well as sleep maintenance. This distinctive alternative has advantageous permissibility and a restricted side-effect profile.
  • Also, the increasing product approvals and product development activities are expected to contribute to the growth of the studied segment over the forecast period. For instance, in October 2022, Idorsia Pharmaceuticals Japan announced positive top-line results of the Japanese Phase 3 study investigating 25 and 50 mg doses of Idorsia's dual orexin receptor antagonist, daridorexant, in 490 randomized adult and elderly patients (30.1% ≥ 65 years) with insomnia disorder.
  • Similarly, in February 2021, Eisai Limited, the Canadian subsidiary of Eisai Inc., received Canadian authorization for its new non-sedative prescription medication, DAYVIGO (lemborexant). In both 5 mg and 10 mg dosages, DAYVIGO is taken for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Due to the apparent benefits associated with the orexin class of drugs, increasing product approvals, and the rising prevalence of insomnia or difficulty falling asleep, the insomnia treatment market is expected to grow steadily during the forecast period.
Insomnia Treatment Market: People Who Had Sleep Problems on Three or More Nights (in Percentage), By Age, United Kingdom, 2021

North America is Expected to Dominate the Insomnia Treatment Market Over the Forecast Period

  • North America is expected to hold a significant share of the insomnia treatment market. The growing need for sleep disorder treatment in the United States and Canada, coupled with the increasing prevalence of sleep disorders, is expected to drive the market over the forecast period.
  • For instance, data published by the Government of Canada in June 2022 mentioned that one-third of Canadians are not getting enough sleep, with thousands of people suffering from insomnia and other sleep disorders. Such incidence of sleep disorders among the population in this region is expected to drive the market's growth. 
  • Also, the increasing government support in the form of funding for insomnia treatment is expected to contribute to the market's growth. For instance, in June 2022, the Minister of Health released funding of USD 2.86 million (CAD 3.8 million) to support research on sleep health and insomnia. The government of Canada supported this initiative through the Canadian Institutes of Health Research (CIHR) in partnership with Esai Limited and Mitacs. Such funding in North America is expected to contribute to the market's growth during the forecast period.
  • Moreover, the presence of key market players' activities, such as collaborations and the R&D of new drugs and product approvals, is expected to boost the growth of the market studied. For instance, in January 2021, Minerva Neurosciences Inc. and Royalty Pharma PLC entered an agreement through which Royalty Pharma will acquire Minerva's royalty interest in seltorexant. Seltorexant, a selective orexin two receptor antagonist, is currently in Phase 3 development for treating major depressive disorder (MDD) with insomnia symptoms.
  • Thus, the growing prevalence of sleep disorders, the presence of major market players, and frequent product launches coupled with increasing government funding for insomnia treatments are expected to contribute to the market's growth over the forecast period in this region.
Insomnia Treatment Market Growth Rate by Region

Insomnia Treatment Industry Overview

The insomnia treatment market is fragmented in nature, owing to the presence of multiple manufacturers. The major players in the market are Merck & Co., Ebb Therapeutics, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Electromedical Products International Inc., Takeda Pharmaceutical Company Ltd, Cerêve Inc., and Innovative Neurological Devices.

Insomnia Treatment Market Leaders

  1. Pfizer Inc.

  2. Sanofi S.A.

  3. Takeda Pharmaceutical Company Ltd.

  4. Merck & Co.

  5. Electromedical Products International Inc.

*Disclaimer: Major Players sorted in no particular order

Insomnia Treatment Market Concentration

Insomnia Treatment Market News

  • May 2022: Idorsia Ltd received marketing authorization from the European Commission for QUVIVIQ, which is is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.
  • January 2022: Idorsia received approval from the United States Food and Drug Administration for QUVIVIQ 25 and 50 mg for the treatment of adults with insomnia, characterized by difficulties with sleep onset and /or sleep maintenance.

Insomnia Treatment Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Stress Due to Highly Active Lifestyles of Individuals

      2. 4.2.2 Side Effects Due to Certain OTC and Prescription Medication

      3. 4.2.3 High Usage of Media Devices Before Sleep

    3. 4.3 Market Restraints

      1. 4.3.1 Misconceptions about the Seriousness of Insomnia

      2. 4.3.2 Patient Non-adherence due to Characteristic Side Effects of Insomnia Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Treatment Type

      1. 5.1.1 By Drug

        1. 5.1.1.1 Benzodiazepines

        2. 5.1.1.2 Nonbenzodiazepines

        3. 5.1.1.3 Orexin Antagonist

        4. 5.1.1.4 Other Drugs

      2. 5.1.2 Devices

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Other Distribution Channels

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co.

      2. 6.1.2 Ebb Therapeutics

      3. 6.1.3 Paratek Pharmaceuticals Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Sanofi SA

      6. 6.1.6 Electromedical Products International Inc.

      7. 6.1.7 Takeda Pharmaceutical Company Ltd

      8. 6.1.8 Cerêve Inc.

      9. 6.1.9 Innovative Neurological Devices

      10. 6.1.10 Eisai Co. Ltd

      11. 6.1.11 Meda Consumer Healthcare

      12. 6.1.12 Purdue Pharma LP

      13. 6.1.13 Pernix Therapeutics

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Insomnia Treatment Market Research FAQs

The Insomnia Treatment Market size is expected to reach USD 3,399.34 million in 2023 and grow at a CAGR of 5.16% to reach USD 4,371.67 million by 2028.

In 2023, the Insomnia Treatment Market size is expected to reach USD 3,399.34 million.

Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Merck & Co. and Electromedical Products International Inc. are the major companies operating in the Insomnia Treatment Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in the Insomnia Treatment Market.

Insomnia Treatment Industry Report

Statistics for the 2023 Insomnia Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Insomnia Treatment analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Insomnia Treatment Market Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!